Leap Therapeutics, Inc. (LPTX) Research

Leap Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing treatments for various cancers. At the forefront of its pipeline is DKN-01, a monoclonal antibody designed to block Dickkopf-related protein 1 (DKK1). This investigational therapy is currently undergoing several clinical trials, targeting a range of malignancies such as esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics has also forged an option and licensing partnership with BeiGene, Ltd., granting them rights to develop and market DKN-01 across Asia (excluding Japan), Australia, and New Zealand. Established in 2011, the company initially operated as HealthCare Pharmaceuticals, Inc., before rebranding to Leap Therapeutics, Inc. in November 2015. Its corporate headquarters are situated in Cambridge, Massachusetts.

Market snapshot

Symbol
LPTX
Price
$0.77
Day change
-3.15%
Market cap
$41.9M
P/E ratio
-2.18x
52-week range
0.2223-3.58
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$5.50

Peer companies

  • Apollomics, Inc. (APLM)
  • Aspire Biopharma Holdings, Inc. (ASBP)
  • Athira Pharma, Inc. (ATHA)
  • BriaCell Therapeutics Corp. (BCTX)
  • Curis, Inc. (CRIS)
  • Citius Pharmaceuticals, Inc. (CTXR)
  • Daré Bioscience, Inc. (DARE)
  • Entero Therapeutics, Inc. (ENTO)

Open Leap Therapeutics, Inc. (LPTX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.